Casdin Capital 13F holdings, Q3 2017
Holdings as of September 30, 2017 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 26 US equity positions worth $354.2m in its Q3 2017 13F filing. The largest position was LOXO ONCOLOGY INC at 9.4% of the reported book, followed by MYOKARDIA INC and ALNY. Against the Q2 2017 filing, it opened 0 new positions, added to 14 and reduced 4 among the top 26 holdings.
What did Casdin Capital own in Q3 2017? Top 26 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2017 |
|---|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC | 9.4% | $33.2m | 360,000 | 0% | held | |
| 2 | MYOKARDIA INC | 6.8% | $24.0m | 560,000 | 42% | added | |
| 3 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 6.6% | $23.5m | 200,000 | 90% | added |
| 4 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 5.9% | $21.0m | 1,400,000 | 0% | held |
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 5.9% | $20.8m | 298,000 | 8% | added | |
| 6 | BLUEBIRD BIO INC | 5.6% | $19.9m | 145,000 | 123% | added | |
| 7 | FOUNDATION MEDICINE INC | 5.4% | $19.3m | 480,000 | 0% | held | |
| 8 | KITE PHARMA INC | 5.4% | $19.1m | 106,000 | 18% | added | |
| 9 | SPARK THERAPEUTICS INC | 5.3% | $18.7m | 209,474 | 23% | added | |
| 10 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.8% | $17.0m | 255,000 | 0% | held |
| 11 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 4.7% | $16.8m | 815,000 | 10% | added |
| 12 | SG7 SAGE THERAPEUTICS INC | 4.2% | $15.0m | 240,000 | -6% | reduced | |
| 13 | GNMK GENMARK DIAGNOSTICS INC | 4.1% | $14.4m | 1,500,000 | 119% | added | |
| 14 | EVH EVOLENT HEALTH INC | Healthcare | 4.0% | $14.2m | 795,000 | 53% | added |
| 15 | GLOBAL BLOOD THERAPEUTICS IN | 3.3% | $11.8m | 380,000 | 77% | added | |
| 16 | AUDENTES THERAPEUTICS INC | 3.2% | $11.2m | 400,000 | 0% | held | |
| 17 | CLOVIS ONCOLOGY INC | 3.0% | $10.5m | 127,500 | -2% | reduced | |
| 18 | CDXS CODEXIS INC | Healthcare | 2.8% | $9.8m | 1,475,000 | 24% | added |
| 19 | ILMN ILLUMINA INC | Healthcare | 2.5% | $8.8m | 44,000 | 40% | added |
| 20 | JOUNCE THERAPEUTICS INC | 1.8% | $6.2m | 399,825 | 150% | added | |
| 21 | T8S TESARO INC | 1.4% | $5.0m | 38,500 | -20% | reduced | |
| 22 | SYROS PHARMACEUTICALS INC | 1.1% | $3.8m | 256,215 | 41% | added | |
| 23 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.9% | $3.2m | 177,500 | 0% | held |
| 24 | EDIT EDITAS MEDICINE INC | Healthcare | 0.9% | $3.2m | 133,333 | 0% | held |
| 25 | FATE FATE THERAPEUTICS INC | Healthcare | 0.6% | $2.2m | 550,000 | 0% | held |
| 26 | OVID OVID THERAPEUTICS INC | Healthcare | 0.5% | $1.8m | 207,500 | -6% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.